Verena Paulitschke

Medical University of Vienna — Austria

Biochemistry, Genetics and Molecular Biology · Life Sciences

19h-index896citations215works0.22yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Melanoma and MAPK Pathways(101), Computational Drug Discovery Methods(44), Immunotherapy and Immune Responses(27), vaccines and immunoinformatics approaches(22), Cancer Immunotherapy and Biomarkers(17)

Publications215 total

Suppl. Figure S3 from ROS Induction Targets Persister Cancer Cells with Low Metabolic Activity in NRAS-Mutated Melanoma
2025Open Access
Suppl. Figure S10 from ROS Induction Targets Persister Cancer Cells with Low Metabolic Activity in NRAS-Mutated Melanoma
2025Open Access
Suppl. Figure S9 from ROS Induction Targets Persister Cancer Cells with Low Metabolic Activity in NRAS-Mutated Melanoma
2025Open Access
Suppl Figure S4 from ROS Induction Targets Persister Cancer Cells with Low Metabolic Activity in NRAS-Mutated Melanoma
2025Open Access
Table ST1 from ROS Induction Targets Persister Cancer Cells with Low Metabolic Activity in NRAS-Mutated Melanoma
2025Open Access
Suppl. Figure S5 from ROS Induction Targets Persister Cancer Cells with Low Metabolic Activity in NRAS-Mutated Melanoma
2025Open Access
Suppl. Figure S13 from ROS Induction Targets Persister Cancer Cells with Low Metabolic Activity in NRAS-Mutated Melanoma
2025Open Access
Table ST4 from ROS Induction Targets Persister Cancer Cells with Low Metabolic Activity in NRAS-Mutated Melanoma
2025Open Access
Suppl. Figure S12 from ROS Induction Targets Persister Cancer Cells with Low Metabolic Activity in NRAS-Mutated Melanoma
2025Open Access
Suppl. Figure S2 from ROS Induction Targets Persister Cancer Cells with Low Metabolic Activity in NRAS-Mutated Melanoma
2025Open Access
Suppl. Figure S6 from ROS Induction Targets Persister Cancer Cells with Low Metabolic Activity in NRAS-Mutated Melanoma
2025Open Access
Suppl. Figure S14 from ROS Induction Targets Persister Cancer Cells with Low Metabolic Activity in NRAS-Mutated Melanoma
2025Open Access
Table ST9 from ROS Induction Targets Persister Cancer Cells with Low Metabolic Activity in NRAS-Mutated Melanoma
2025Open Access
Suppl. Figure S15 from ROS Induction Targets Persister Cancer Cells with Low Metabolic Activity in NRAS-Mutated Melanoma
2025Open Access
Table ST7 from ROS Induction Targets Persister Cancer Cells with Low Metabolic Activity in NRAS-Mutated Melanoma
2025Open Access
Suppl Figure S11 from ROS Induction Targets Persister Cancer Cells with Low Metabolic Activity in NRAS-Mutated Melanoma
2025Open Access
Suppl. Figure S8 from ROS Induction Targets Persister Cancer Cells with Low Metabolic Activity in NRAS-Mutated Melanoma
2025Open Access
Suppl.Figure S16 from ROS Induction Targets Persister Cancer Cells with Low Metabolic Activity in NRAS-Mutated Melanoma
2025Open Access
Suppl. Figure S7 from ROS Induction Targets Persister Cancer Cells with Low Metabolic Activity in NRAS-Mutated Melanoma
2025Open Access
Table ST5 from ROS Induction Targets Persister Cancer Cells with Low Metabolic Activity in NRAS-Mutated Melanoma
2025Open Access
page 1 of 11Next →

Frequent Co-authors

Christopher Gerner(26), Andrea Bileck(21), Nina Zila(18), Rainer Kunstfeld(17), Mitchell P. Levesque(17), Ossia M. Eichhoff(16), Phil F. Cheng(16), Reinhard Dummer(16), Thomas Mohr(14), Alexander Leitner(14), Hubert Pehamberger(13), Anja Irmisch(10), Corinne I. Stoffel(9), Jan Käsler(9), Luzia Briker(9), Patrick Turko(9), Gergely Karsai(9), Nicola Zamboni(9), Zsolt Balázs(9), Aizhan Tastanova(9)